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Abstract
The various granule subtypes of the human neutrophil differ in propensity for exocytosis. As a rule, granules formed at late stages of
myelopoiesis have a higher secretory potential than granules formed inmore immature myeloid cells. Neutrophils contain four closely related a-
defensins, which are stored in a subset of azurophil granules. These defensin-rich azurophil granules (DRG) are formed later than defensin-poor
azurophil granules, near the promyelocyte/myelocyte transition. In order to characterize the secretory properties of DRG, we developed a
sensitive and accurate ELISA for detection of the neutrophil a-defensins HNP 1–3. This allowed us to quantify the exocytosis of a-defensins
and markers of azurophil (myeloperoxidase), specific (lactoferrin) and gelatinase (gelatinase) granules from neutrophils stimulated with
different secretagogues. The release pattern of a-defensins correlated perfectly with the release of myeloperoxidase and showed no resemblance
to the exocytosis of lactoferrin or gelatinase. This finding was substantiated through subcellular fractionation experiments. In conclusion,
despite a distinct profile of biosynthesis, DRG are indistinguishable from defensin-poor azurophil granules with respect to exocytosis. Thus, in
contrast to peroxidase-negative granules, azurophil granules display homogeneity in their availability for extracellular release.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Granules of human neutrophils are formed sequentially
during myeloid cell differentiation. Azurophil (peroxidase-
positive) granules are the first to appear. These granules,
traditionally defined by their content of myeloperoxidase, are
formed at the promyelocyte stage of neutrophil development
[1]. Peroxidase-negative granules are formed in myelocytes,
metamyelocytes, band cells and segmented neutrophils [1,2],
and can be divided into two subsets, which occur succes-
sively: specific granules, identified by a high content of
lactoferrin, and gelatinase granules, identified by gelatinase
[3]. The various granule subtypes differ in accessibility for
exocytosis. Gelatinase granules are the most easily mobi-
lized, followed by specific granules and azurophil granules
[4]. Thus, as a rule, granules formed at later stages of
myelopoiesis have a higher secretory potential than granules
formed in more immature myeloid cells.
Alpha-defensins are important antimicrobial peptides [5].
The human neutrophil granulocyte contains four closely
related a-defensins (HNP 1–4), which are stored in a subset
of azurophil granules [6,7]. These defensin-rich azurophil
granules (DRG) are formed later than defensin-poor azur-
ophil granules, near the promyelocyte/myelocyte transition
[7]. The late appearance of DRG is a consequence of the
biosynthetic window of neutrophil a-defensins. Whereas
other matrix proteins of azurophil granules like myeloper-
oxidase, proteinase-3, and elastase are synthesized through-
out the promyelocytic stage, production of a-defensins is
first initiated in late promyelocytes [8]. Furthermore, in
contrast to other matrix proteins of azurophil granules,
expression of a-defensins is dependent on the CCAAT/
enhancer binding protein q, a transcription factor that is
also essential for the expression of a variety of specific and
gelatinase granule matrix proteins [9,10]. Taken together,
these features have led to speculations that DRG may have
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their own place in the functional hierarchy of neutrophil
granules. The present study was undertaken in order to
characterize the secretory properties of DRG.
2. Materials and methods
2.1. Isolation of neutrophils
Human neutrophils were isolated from freshly prepared
buffy coats supplied by the hospital blood bank. Erythro-
cytes were sedimented for 45 min by addition of an equal
volume of 2% Dextran T-500 (Amersham Pharmacia Bio-
tech AB, Uppsala, Sweden) in 0.9% saline. The leukocyte-
rich supernatant was siphoned off, and the cells centrifuged
at 200 g for 10 min. Cells were resuspended in 0.9%
saline and centrifuged through Lymphoprep (Nycomed
Pharma AS, Oslo, Norway) at 400 g for 30 min to remove
mononuclear cells. Remaining erythrocytes were lysed by
hypotonic shock in ice-cold water for 30 s followed by
restoration of tonicity by addition of 1.8% saline. The cells
were subsequently washed once in saline and resuspended
in the desired buffer. All steps except Dextran sedimentation
were performed at 4 jC.
2.2. Subcellular fractionation
Isolated neutrophils, resuspended at 3 107 cells/ml in
0.9% saline, were incubated for 5 min with 5 mM diisopro-
pylflourophosphate (DFP, Aldrich Chemical Company, Mil-
waukee, WI, USA) and centrifuged at 200 g for 10 min.
The pelleted cells were resuspended at 3 107 cells/ml in
disruption buffer (100 mMKCl, 3 mMNaCl, 1 mMNa2ATP,
3.5 mM MgCl2, 10 mM PIPES, pH 7.2) containing 0.5 mM
phenylmethylsulfonyl fluoride (PMSF) and disrupted by
nitrogen cavitaton (pressurized for 5 min) as described [11].
Nuclei and unbroken cells were pelleted by centrifugation at
400 g for 15 min. Ten milliliters of the postnuclear super-
natant was applied on top of a three-layer Percoll gradient
(1.05/1.09/1.12 g/ml) [12] containing 0.5 mM PMSF and
centrifuged for 30 min at 37000 g. This resulted in a
gradient with four clearly visible bands: the bottom band
(a-band) containing the azurophil granules, the low inter-
mediate band (h1-band) containing the specific granules, the
high intermediate band (h2) containing gelatinase granules
and the top-band (g-band) containing plasma membranes and
secretory vesicles. The cytosol was present above the g-band
on top of the Percoll. The gradient was collected in fractions
of 1 ml by aspiration from the bottom of the tube, and the
content of granule markers in the different fractions was
determined by ELISA as described below.
2.3. Purification of neutrophil a-defensins
Following subcellular fractionation, the a-band contain-
ing azurophil granules was harvested manually, and Percoll
was removed by ultracentrifugation. Isolated granules were
lysed in phosphate buffered saline (PBS; 136 mM NaCl2,
2.7 mM KCl, 8 mM Na2HPO4, 1.46 mM KH2PO4, pH 7.4)
containing 40 mM n-octylglycosid-h-D-glucopyranoside
(Calbiochem, La Jolla, CA, USA) and rotated overnight at
4 jC. The next day, membranes were pelleted by ultra-
centrifugation for 30 min at 20000 g, and the supernatant,
containing the granule matrix proteins, was dialysed against
a 50 mM sodium-phosphate buffer, pH 6.7, with 20 mM n-
octylglycosid-h-D-glucopyranoside. Isolated azurophil gran-
ule proteins were subjected to cation exchange chromatog-
raphy on a MonoS column using A¨KTA-FPLC (Amersham
Pharmacia Biotech). Most of the bound material was eluted
with 1.0 M NaCl, pH 6.7. Alpha-defensins were subse-
quently eluted with 0.5 M NaOH. The purity of the eluted
material was ascertained by sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis (SDS-PAGE), which showed
a single band in the expected low molecular weight zone
after staining with Coomassie Blue (not shown). The
defensins were dialysed into PBS using Slide-A-LyzerR
3.5 K Dialysis Cassettes (Pierce, Rockford, IL, USA) and
stored at  20 jC until further use. The concentration of a-
defensins in the PBS suspension was determined spectro-
photometrically using the specific extinction coefficients for
HNP-1 and -3 at 280 nm.
2.4. Amino acid sequence analysis of purified a-defensins
For amino acid sequence analysis, an aliquot of the
purified neutrophil a-defensins preparation was blotted
onto a PVDF membrane as described below. The analysis
was performed for 10 residues in a 494 A Procise Protein
Sequencer (PerkinElmer, Palo Alto, CA) using the blot
cartridge and PVDF cycles. All reagents and solvents
were supplied by PerkinElmer. The results confirmed that
the preparation contained a mixture of neutrophil a-
defensins, HNP 1–3. HNP 4, which constitutes between
1% and 2% of the defensins in neutrophils [13], was not
detected.
2.5. Generation of polyclonal anti-a-defensin antibodies
Purified neutrophil a-defensins were conjugated to
ovalbumin (ICN Biochemicals Inc, Aurora, OH, USA)
by N-succinimidyl 3-(2-pyridyldithio)propionate (Sigma,
St. Louis, MO, USA), essentially as described [14].
Immunization was performed at Dako A/S (Glostrup,
Denmark). Rabbits received subcutaneous injections of
50 Ag a-defensin conjugated to 400 Ag ovalbumin in
100 Al incomplete Freunds adjuvant four times at 2-week
intervals and thereafter once a month. The IgG fraction of
the obtained poly-clonal anti-defensin/anti-ovalbumin anti-
serum was isolated on a protein A column using A¨KTA-
FPLC (Amersham Pharmacia Biotech). The antibodies
were eluted with 3 M KSCN and immediately dialysed
against PBS containing 0.1% sodium azide. A portion of
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the IgG antibodies were biotinylated as described [15]. The
biotinylated antibodies were dialysed into PBS and stored
with 0.1% sodium azide, protected from light. Subse-
quently, the ovalbumin-reactive antibodies were removed
from the protein A purified IgG fraction by affinity
chromatography on a column with ovalbumin coupled to
CNBr-activated Sepharose (Amersham Pharmacia Bio-
tech).
2.6. SDS-PAGE and immunoblotting
SDS-PAGE [16] and immunoblotting [17] were per-
formed with Mini-Protean 3 Cells and Mini Trans-Blot
Electrophoretic Transfer Cells according to the instructions
given by the manufacturer (Bio-Rad, Hercules, CA, USA).
For immunoblotting, polyvinylidene difluoride (PVDF)
membranes (Millipore, Bedford, MA, USA) were blocked
for 1 h with 5% skimmed milk in PBS after transfer of
proteins from the 14% polyacrylamide gels. The PDVF
membranes were incubated overnight with rabbit polyclonal
anti-defensin antiserum or protein A purified biotinylated
IgG antibodies. The next day, membranes were incubated
for 2 h with horseradish peroxidase-conjugated porcine
antibodies to rabbit immunoglobulins (Dako P217) and
visualized by diaminobenzidine–metal concentrate and sta-
ble peroxide substrate buffer (Pierce).
2.7. Generation of an ELISA for neutrophil a-defensins
An ELISA for the neutrophil a-defensins HNP 1–3 was
generated using 96-well flat-bottom immunoplates (Nunc,
Roskilde, Denmark). First, checkerboard titrations were
performed with different concentrations of antigen, capture
antibody, detecting antibody, and avidin–peroxidase. The
dilutions mentioned below were found to be optimal in an
ELISA with a detection limit of 3.0 ng/ml. The procedure
was as follows:
1. Plates were coated overnight with anti-a-defensin IgG
antibodies diluted 1/500 in carbonate buffer (50 mM
Na2CO3/NaHCO3, pH 9.6).
2. Additional binding sites were then blocked by incubation
with 200 Al/well of buffer A (0.5 M NaCl, 3 mM KCl, 8
mM Na2HPO4/KH2PO4, 1% BSA, 1% Triton X-100, pH
7.2).
3. Samples and standards (purified neutrophil a-defensins
ranging from 3125 to 200 ng/ml) were applied.
4. Biotinylated antibodies, diluted 1/125, were added.
5. Avidin–peroxidase (Dako P347), diluted 1/5000, was
added.
6. Color was developed by a 30 min incubation period in
buffer B (0.1 M sodium phosphate/0.1 M citric acid
buffer, pH 5.0), containing 0.04% o-phenylenediamine
(Kem-En-Tec, Copenhagen, Denmark) and 0.03%
H2O2, and stopped by addition of 100 Al/well of 1 M
H2SO4.
The plates were washed three times in buffer C (0.5 M
NaCl, 3 mM KCL, 8 mM Na2HPO4/KH2PO4, 1% Triton X-
100, pH 7.2) using a Skanwasher 410 (Skatron, Roskilde,
Denmark) between each step. Before color development, an
additional wash in buffer B was included. All incubations
were performed at room temperature for 1 h after adding 100
Al of sample to each well. Samples and antibodies were dilu-
ted in buffer A. Absorbance was read at 492 nm in a Multi-
scan Ascent ELISA reader (Labsystems, Helsinki, Finland).
2.8. Additional ELISAs
Myeloperoxidase, lactoferrin, and gelatinase were meas-
ured by ELISA as described [18,19]. General ELISA proce-
dures were as described above for the a-defensin ELISA.
2.9. Release experiments
Isolated neutrophils were resuspended in Krebs–Ringer
phosphate (KRP, 130 mM NaCl, 5 mM KCl, 1.27 mM
MgSO4, 0.95 mM CaCl2, 5 mM glucose, 10 mM NaH2PO4/
Na2HPO4, pH 7.4) at a concentration of 3 107 cells/ml.
For stimulation with either 1.0 AM Ionomycin (Calbio-
chem), 5 Ag/ml phorbol myristate acetate (PMA, Sigma)
or 10.0 nM N-formylmethionyl-leucyl-phenylalanine
(fMLP, Sigma), neutrophils were preincubated for 5 min
at 37 jC. After addition of the stimulatory agent, the cells
were incubated at 37 jC for 15 min. For stimulation with
Cytochalasin B/fMLP, the cells were preincubated for 5 min
at 37j with 5.0 AM cytochalasin B (Sigma) followed by
stimulation for 15 min at 37 jC with 1.0 AM fMLP. In all
settings, stimulation was terminated by dilution with 2
volumes of ice-cold KRP and centrifugation at 200 g for
6 min. Control cells were kept on ice until dilution in KRP.
The supernatant (S0) containing exocytosed material was
removed, and the pelleted cells were resuspended in saline.
Release of a-defensins, myeloperoxidase, lactoferrin, and
gelatinase was calculated as amount in S0/amount in
(S0 + Pellet) and expressed as a percentage.
3. Results
3.1. Specificity of anti-defensin antibodies
The polyclonal rabbit anti-defensin antiserumwas specific
for neutrophil a-defensins as evidenced by Western blotting
of a neutrophil homogenate (postnuclear supernatant), elec-
trophoresed under reducing conditions (Fig. 1A). The IgG
fraction of the antibodies retained the ability to bind a-
defensins in immunoblotting after biotinylation (Fig. 1B).
3.2. ELISA accuracy and reproducibility
A standard curve for neutrophil a-defensins is shown in
Fig. 2. Near parallelism between the standard curve and
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serial two-fold dilutions of either neutrophil homogenate or
exocytosed material from neutrophils stimulated with 0.5
AM Ionomycin was observed (Fig. 2). Irrelevant neutrophil
proteins are therefore unlikely to interfere with the ELISA.
The accuracy of the assay was determined by adding
different amounts of purified a-defensins to azurophil
granule homogenate and exocytosed material from Ionomy-
cin-stimulated neutrophils. The average recovery was
99.97%F 4.14 (S.D.) (azurophil granule homogenate,
n = 4) and 102.21F1.07 (S.D.) (exocytosed material,
n = 4). Reproducibility was estimated by repeated measure-
ments on azurophil granule homogenate and exocytosed
material. The average intra-assay coefficient of variation
was 4.9% (4.06% for the azurophil granule homogenate
(n = 112); 5.8% for the exocytosed material (n = 122)). The
average day-to-day coefficient of variation was 8.6%
(9.25% for the azurophil granule homogenate (n = 5);
8.1% for exocytosed material (n = 6)).
3.3. Exocytosis of a-defensins from neutrophils during
stimulation with various secretagogues
The release of a-defensins and classical markers of
azurophil granules (myeloperoxidase), specific granules
(lactoferrin), and gelatinase granules (gelatinase) in
response to stimulation with Ionomycin, Cytochalasin B/
fMLP, PMA, and fMLP is summarized in Fig. 3. The
observed releases of myeloperoxidase, lactoferrin, and
gelatinase are in full agreement with earlier findings
[4,12] and confirm the different availability for exocytosis
of neutrophil granule subsets (gelatinase granules>specific
granules>azurophil granules). The release pattern of a-
defensins correlated perfectly with the release of myeloper-
oxidase and showed no resemblance to the exocytosis of
lactoferrin or gelatinase. Of note, a-defensins were exocy-
tosed to a similar extend as MPO during stimulation with
powerful agonists of azurophil granule release (Ionomycin,
Cytochalasin B/fMLP). Furthermore, when cells were
stimulated with PMA, which predominantly induces release
of peroxidase-negative granules, the exocytosis of a-defen-
sins was less than 5%, whereas the mean exocytosis of
lactoferrin was 45.0%. These findings demonstrate that
Fig. 2. Standard curve of neutrophil a-defensins and serial two-fold dilutions of a neutrophil homogenate and exocytosed material from Ionomycin-stimulated
neutrophil granulocytes. Dilutions of neutrophil homogenate and exocytosed material were prepared to obtain approximately the same absorbance as observed
with the lowest dilution of standard. Two-fold dilutions of samples are expressed in percentage of the absorbance obtained with the lowest dilution of the
sample concerned (set to 100%).
Fig. 1. Specificity of rabbit polyclonal antibodies against neutrophil a-
defensins. SDS-PAGE was performed on a neutrophil homogenate
(postnuclear supernatant) from 3 107 neutrophils/ml, diluted 10-fold in
SDS sample buffer. (A) Immunoblotting with polyclonal anti-defensin
antiserum. (B) Immunoblotting with affinity-purified IgG antibodies after
biotinylation. In both lanes, a single band with the expected molecular
weight is seen, indicating that the antibodies are specific and retain their
reactivity against a-defensins after purification and biotinylation. Molecular
weight markers are indicated on the left.
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DRG do not have a unique release profile but share secre-
tory properties with other azurophil granules.
3.4. Subcellular localization of a-defensins in mature
neutrophils
The subcellular localization of a-defensins in unstimu-
lated, mature neutrophils was determined in subcellular
fractionation experiments using three-layer Percoll gradients
(Fig. 4). High concentrations of a-defensins were detected
only in the five higher density fractions (1–5) with a peak in
the second fraction. In comparison, myeloperoxidase was
found in relatively high concentrations throughout the
fractions containing azurophil granule constituents with a
peak in fraction 3. These findings are consistent with
previous observations [6,7] and show that neutrophil a-
defensins are confined to a subset of azurophil granules
physically characterized by the highest density of all known
granule subtypes. Subcellular fractionation of Ionomycin-
stimulated neutrophils showed a uniform depletion of mye-
loperoxidase and a-defensins in fractions containing sig-
nificant amounts of these markers (Fig. 4, fractions 1–7),
Fig. 4. Subcellular fractionation of control (—) and ionomycin-stimulated (- - - -) neutrophils on three-layer Percoll density gradients. Subcellular distribution
of a-defensins (o), myeloperoxidase (MPO, n), lactoferrin (LF, E) and gelatinase ( ). Mean values of three independent experiments are shown.
Fig. 3. Exocytosis of neutrophil granule markers during stimulation. Cells were stimulated as follows: Ionomycin, 1 AM; Cyt/fMLP (Cytochalasin B/fMLP),
5.0 AM/1.0 AM; PMA (phorbol myristate acetate), 5 Ag/ml; fMLP (N-formylmethionyl-leucyl-phenylalanine), 10 nM. There was no significant difference
between the exocytosis of a-defensins and myeloperoxidase (MPO) under any conditions ( P > 0.05 in all settings; paired t-test). The release of lactoferrin was
significantly higher than the release of a-defensins in response to all stimuli ( P < 0.02), while gelatinase was exocytosed to a greater extent than both a-
defensins and lactoferrin ( P< 0.05). Bars are means of at least three experiments. Error bars represent S.D.
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clearly establishing that defensin-rich and defensin-poor
azurophil granules are mobilized to the same extent during
calcium ionophore-stimulation. The localization of lactofer-
rin (specific granules) and gelatinase (gelatinase granules)
was as expected [12]. The distribution profiles of lactoferrin
and a-defensins were without significant overlap. Thus,
despite the almost overlapping biosynthetic windows of a-
defensins and lactoferrin in myelopoiesis [8], these markers
are restricted to late azurophil and specific granules, respec-
tively.
4. Discussion
The differences in propensity for exocytosis of neutrophil
granule subsets provide the neutrophil with the ability to
differentiate its release of antimicrobial proteins in response
to inflammatory challenge. Furthermore, the functional
hierarchy of granules allows a sequential translocation of
adhesion molecules to the plasma-membrane of the acti-
vated neutrophil. Membrane-bound proteins needed for
neutrophil extravasation and diapedesis are localized to
the most readily mobilizable intracellular compartments,
i.e. secretory vesicles, gelatinase granules and specific
granules [20].
Among peroxidase-negative granules, a hierarchy of
mobilization has been convincingly demonstrated. Specific
granules, which are formed in myelocytes and metamyelo-
cytes, have a lower secretory potential than gelatinase
granules, which are formed in band cells and segmented
neutrophils [2,12]. The molecular mechanisms underlying
the differential secretion of peroxidase-negative granule
subsets are incompletely understood, but probably involve
a lower density of docking/fusion proteins on granules
formed at early stages of neutrophil development than on
granules formed late in myelopoiesis [21,22].
No docking/fusion molecules have been identified in the
membranes of azurophil granules so far, and these granules
undergo very limited exocytosis during stimulation with
most inflammatory mediators [4,20,23]. It is therefore
believed, that azurophil granules are mobilized primarily
to phagosomes after engulfment of opsonized targets. How-
ever, a recent study has challenged this simplistic view on
azurophil granules by showing that the specific granule
protein hCAP-18 is processed to the antimicrobial peptide
LL-37 by extracellular cleavage with the azurophil matrix
protein proteinase-3 [24]. Furthermore, neutrophil a-defen-
sins induce selective chemotaxis of CD45RA/CD4 T cells,
CD8 T cells, and immature dendritic cells at nanomolar
concentrations [25,26]. Together, these observations clearly
demonstrate a physiological role for azurophil granule
proteins after exocytosis.
Limited information is available regarding the secretory
properties of azurophil granule subsets [27]. Based on
morphology, density, content, and timing of formation, at
least two populations of azurophil granules can be identi-
fied: early-appearing defensin-poor and late-appearing
defensin-rich granules [6,7]. In order to compare the mobi-
lization kinetics of these granules, we developed a sensitive
and accurate ELISA for detection of the neutrophil a-
defensins HNP 1–3. This allowed us to quantify the
extracellular release of a-defensins from neutrophils stimu-
lated with different secretagogues and to study the exocy-
tosis of defensin-rich and defensin-poor azurophil granules
in subcellular fractionation experiments. Our investigations
show, that DRGs are indistinguishable from other azurophil
granules with respect to exocytosis. This finding raises the
question of why azurophil granule heterogeneity exists,
when, in contrast to peroxidase-negative granules, all azur-
ophils are exocytosed to the same extent during stimulation.
It has previously been shown, that the specific granule
protein NGAL will be targeted to azurophil granules if the
biosynthetic window of the protein is changed from the
myelocyte stage to the promyelocyte stage [28]. However,
such retargeting results in a slow intragranular degradation
of NGAL, probably mediated by one of the many proteases
contained within azurophil granules. This observation dem-
onstrates, that not all granule proteins can exist together.
Similarly, it could be speculated, that a-defensins are con-
fined to DRG in order to prevent some inappropriate
interaction between a-defensins and constituents of defen-
sin-poor azurophil granules. Alternatively, a-defensins may
be targeted to late-appearing azurophil granules simply as a
consequence of their biosynthetic window and a depend-
ency on azurophil granule proteases for their correct pro-
cessing and intracellular retention [29].
In conclusion, this study provides a characterization of
the secretory properties of DRG. Despite a distinct profile of
biosynthesis, DRG are indistinguishable from defensin-poor
azurophil granules with respect to exocytosis. Thus, unlike
peroxidase-negative granules, azurophil granules display
homogeneity in their availability for extracellular release.
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